1Centre for Medical Education, Queen's University, Belfast, 2MRC Molecular Haematology
Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine …

Polycythaemia vera (PV) is a chronic blood cancer; its clinical features are dominated by
myeloproliferation (erythrocytosis, often leucocytosis and/or thrombocytosis) and a tendency …

In developing a management plan for polycythaemia vera, the following issues must be
considered. First, polycythaemia vera is a clonal disorder with the primary defect residing in …

Erythrocytosis is an increase in the number of red blood cells. In a recent study from the
United States, the prevalence of primary erythrocytosis (known as polycythaemia vera) was …

We reviewed current guidelines on the management of polycythemia vera. For questions
regarding the diagnostic investigation of erythrocytosis and the utility of specific laboratory …

This review focuses on polycythemia vera (PV)—its diagnosis, cellular and genetic
pathology, and management. In Section I, Dr. Pearson, with Drs. Messinezy and Westwood …

Erythrocytosis is frequently encountered as an incidental abnormality on laboratory testing
that reveals persistent elevation of the hematocrit level (> 52% in men and> 48% in women) …

Methods This multicentric retrospective study included PV patients enrolled in a pan-
provincial registry of the chronic myeloid leukemia (CML) and myeloproliferative neoplasms …

Background Current treatment recommendations for patients with polycythemia vera call for
maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested …

Major causes of morbidity and mortality in polycythemia vera (PV) and essential
thrombocythemia (ET) are represented by thrombosis and bleeding, progression to …